Director Nancy Chang's Stake Shifts to 5.9% Amidst Mandatory Preferred Stock Conversion

summarizeSummary

Director Nancy T. Chang's beneficial ownership in Galera Therapeutics has been updated to 5.9% of common stock, reflecting her participation in a recent mandatory conversion of Series B Preferred Stock and prior share purchases.

check_boxKey Events

• Director's Updated Ownership

  Director Nancy T. Chang now beneficially owns 8,921,543 shares of common stock, representing 5.9% of the outstanding class.

• Mandatory Preferred Stock Conversion

  On April 7, 2026, 1,180,611 shares of Series B Preferred Stock held by Ms. Chang were mandatorily converted into common stock by the Issuer, as part of broader conversions previously reported on April 9, 2026.

• Prior Significant Investment

  In December 2024, Ms. Chang purchased 7,644,932 shares of common stock for approximately $499,979 as part of a private placement.

• Dilution of Percentage Stake

  Despite increasing her absolute share count, Ms. Chang's percentage ownership decreased from 10.1% (as of December 30, 2024) to 5.9% due to a significant increase in the total outstanding common shares.

auto_awesomeAnalysis

This Schedule 13D provides a detailed history of Director Nancy T. Chang's investment in Galera Therapeutics, culminating in her current 5.9% beneficial ownership. While she made a significant purchase of common stock in December 2024, her percentage ownership has decreased from 10.1% to 5.9% due to substantial overall share dilution from other capital events, including the mandatory conversion of preferred stock on April 7, 2026. This filing offers specific insider context to the broader preferred stock conversions recently disclosed by the company, highlighting how a key director's relative stake has been impacted by the company's capital restructuring efforts, especially in light of the company's previously reported going concern warning.